This report collects all COVID-19 long-term care facilities (LTCF) data reported to ECDC from 2021 and concludes the EU/EEA LTCF COVID-19 specific surveillance data collection from 2021-2023.
This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 3.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0 [5], updated to version 2.0 [6].
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 21-27 January 2024 and includes updates on SARS-CoV-2, influenza, cholera, chikungunya, dengue and zika.
This core protocol for ECDC studies of vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2 or with influenza, version 2.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with Severe Acute Respiratory Infection (SARI), already published as version 1.0.
This document provides practical guidance to EU/EEA Member States willing to implement a pilot study for the harmonised and coordinated targeted genomic surveillance of SARS-CoV-2 at selected international points of entry (PoE), to complement national and international genomic surveillance.
In a Threat Assessment Brief released today, the European Centre for Disease Prevention and Control (ECDC) assesses the overall level of risk to the EU/EEA associated with the spread of the Omicron XBB.1.5 SARS-CoV-2 sub-lineage as low for the general population.
XBB.1.5 is a sub-lineage of the SARS-CoV-2 lineage XBB, and is currently estimated to have a large growth advantage over previously circulating lineages in North America (109%) and Europe (113%).